orthovita

Biologics

Josh SandbergJune 1, 2011
746

Orthovita shareholders sue to stop $316 million Stryker buyout

Shareholders of Orthovita Inc. (NSDQ: VITA), a Malvern, Pa.-based orthopedic biologics maker, are suing over a proposed $316 million merger by…
Read More »
Josh SandbergMay 31, 2011
712

Stryker Launches Tender Offer

Orthopedic devices giant Stryker Corp (SYK – Analyst Report) has commenced its $3.85 per share tender offer for its previously announced acquisition…
Read More »
Biologics

Josh SandbergMay 16, 2011
775

Stryker Announces Definitive Agreement to Acquire Orthovita, Inc. for $3.85 Per Share in Cash

Kalamazoo, Michigan – May 16, 2011- Stryker Corporation (NYSE:SYK) announced today a definitive agreement to acquire Orthovita, Inc. (Nasdaq:VITA), a…
Read More »
Josh SandbergApril 13, 2011
1,508

Orthovita Launches the Aliquot™ Directional Bone Tamp

MALVERN, Pennsylvania, Wednesday, April 13, 2011 – Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today the launch…
Read More »
Josh SandbergApril 11, 2011
1,424

Orthovita Announces Presentation of Clinical Results Evaluating Vitagel™ Surgical Hemostat in Reducing Blood Loss During Primary Unilateral Total Knee Arthroplasty

MALVERN, Pennsylvania, Monday, April 11, 2011 – Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, is pleased to announce…
Read More »
Josh SandbergDecember 9, 2010
877

Orthovita Gets FDA Clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Orthovita, Inc., an orthobiologics and biosurgery company, said that it received 510(k) clearance from the U.S. Food and Drug Administration…
Read More »
Josh SandbergDecember 7, 2010
1,514

Orthovita Receives FDA Clearance for Vitoss™ Bioactive Foam-2X Bone Graft Substitute

MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the…
Read More »
Josh SandbergOctober 21, 2010
769

Orthovita Announces 2010 Third Quarter Product Sales

MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, today announced that product sales for the third quarter…
Read More »
Josh SandbergOctober 7, 2010
504

Orthovita Announces Presentation of Cortoss 24-Month Pivotal Study Results at the 25th Annual Meeting of the North American Spine Society

MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, is pleased to announce that Hyun W. Bae, M.D.,…
Read More »
Josh SandbergJuly 22, 2010
661

Medtronic Spinal & Biologics’ Reign in the US Vertebral Compression Fracture Treatment Market Threatened as New Players Emerge

WALTHAM, Mass., July 22 /PRNewswire/ — According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Medtronic Spinal…
Read More »
Josh SandbergMarch 11, 2010
782

Orthovita Reports 2009 Fourth Quarter and Year-End Financial Results

MALVERN, Pa., Mar 10, 2010 (BUSINESS WIRE) — –Fourth quarter 2009 operating income of $385,000 compared to an operating loss…
Read More »
Josh SandbergFebruary 26, 2010
644

Orthovita to Present at the Canaccord Adams Musculoskeletal Conference

MALVERN, Pa.–(BUSINESS WIRE)–Orthovita, Inc. (NASDAQ:VITA), an orthobiologics and biosurgery company, announced today that it will present at the Canaccord Adams…
Read More »
Josh SandbergFebruary 12, 2010
684

Has Orthovita’s Fight Finally Ended?

Article preview reprinted from IN VIVO – December/January, 2010 Orthovita had spent the past eight years building up a small commercial…
Read More »